The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils

Franco Capsoni, Annamaria Ongari, Gualtiero Colombo, Flavia Turcatti, Anna Catania

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Natural melanocortin peptides exert broad effects on the host and they have remarkable therapeutic potential. However, successful use of melanocortins as therapeutic agents depends on the design of molecules that have more stable pharmacological profiles. The synthetic peptide (CKPV)2, based on the C-terminal sequence of α-melanocyte stimulating hormone (α-MSH), has anti-tumor necrosis factor-α (TNF-α) effects in vitro and in vivo and is a promising candidate to treat inflammation. Because neutrophil activity is a major target for anti-inflammatory therapies, we determined whether (CKPV)2 modulates human neutrophil functions in vitro. Incubation of freshly-separated human neutrophils with 10-12-10-6 M (CKPV)2 significantly inhibited activities relevant to the inflammatory reaction. Neutrophil migration toward the two chemoattractants interleukin 8 (IL-8) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) was significantly inhibited by (CKPV)2. (CKPV)2 also inhibited reactive oxygen intermediate (ROI) production induced by phorbol 12-myristate 13-acetate (PMA), but not that induced by fMLP. Because these effects of (CKPV)2 were abolished by the adenylyl cyclase inhibitor 2′,5′-dideoxyadenosine (ddAdo), they appear to be cAMP-dependent. Finally, the peptide reduced lipopolysaccharide (LPS)-stimulated expression of TNF-α, interleukin-1β (IL-1β), interleukin-8 (IL-8), and intercellular adhesion molecule 1 (ICAM-1), as well as TNF-α protein release in cell supernatants. The data indicate that (CKPV)2 modulates broad cAMP-dependent, anti-inflammatory pathways in human neutrophils.

Original languageEnglish
Pages (from-to)2016-2022
Number of pages7
JournalPeptides
Volume28
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Melanocortins
Neutrophils
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Interleukin-8
Peptides
Dideoxyadenosine
methionyl-leucyl-phenylalanine
Melanocyte-Stimulating Hormones
N-Formylmethionine Leucyl-Phenylalanine
Chemotactic Factors
Intercellular Adhesion Molecule-1
Interleukin-1
Adenylyl Cyclases
Lipopolysaccharides
Acetates
Oxygen
Molecules
Therapeutics
Pharmacology

Keywords

  • α-Melanocyte stimulating hormone (α-MSH)
  • (CKPV)
  • Chemotaxis
  • Human neutrophils
  • Lipopolysaccharide (LPS)
  • Melanocortin peptides
  • Respiratory burst

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils. / Capsoni, Franco; Ongari, Annamaria; Colombo, Gualtiero; Turcatti, Flavia; Catania, Anna.

In: Peptides, Vol. 28, No. 10, 10.2007, p. 2016-2022.

Research output: Contribution to journalArticle

Capsoni, Franco ; Ongari, Annamaria ; Colombo, Gualtiero ; Turcatti, Flavia ; Catania, Anna. / The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils. In: Peptides. 2007 ; Vol. 28, No. 10. pp. 2016-2022.
@article{54f2a00b9c594d618cd8238b8bcfb98c,
title = "The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils",
abstract = "Natural melanocortin peptides exert broad effects on the host and they have remarkable therapeutic potential. However, successful use of melanocortins as therapeutic agents depends on the design of molecules that have more stable pharmacological profiles. The synthetic peptide (CKPV)2, based on the C-terminal sequence of α-melanocyte stimulating hormone (α-MSH), has anti-tumor necrosis factor-α (TNF-α) effects in vitro and in vivo and is a promising candidate to treat inflammation. Because neutrophil activity is a major target for anti-inflammatory therapies, we determined whether (CKPV)2 modulates human neutrophil functions in vitro. Incubation of freshly-separated human neutrophils with 10-12-10-6 M (CKPV)2 significantly inhibited activities relevant to the inflammatory reaction. Neutrophil migration toward the two chemoattractants interleukin 8 (IL-8) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) was significantly inhibited by (CKPV)2. (CKPV)2 also inhibited reactive oxygen intermediate (ROI) production induced by phorbol 12-myristate 13-acetate (PMA), but not that induced by fMLP. Because these effects of (CKPV)2 were abolished by the adenylyl cyclase inhibitor 2′,5′-dideoxyadenosine (ddAdo), they appear to be cAMP-dependent. Finally, the peptide reduced lipopolysaccharide (LPS)-stimulated expression of TNF-α, interleukin-1β (IL-1β), interleukin-8 (IL-8), and intercellular adhesion molecule 1 (ICAM-1), as well as TNF-α protein release in cell supernatants. The data indicate that (CKPV)2 modulates broad cAMP-dependent, anti-inflammatory pathways in human neutrophils.",
keywords = "α-Melanocyte stimulating hormone (α-MSH), (CKPV), Chemotaxis, Human neutrophils, Lipopolysaccharide (LPS), Melanocortin peptides, Respiratory burst",
author = "Franco Capsoni and Annamaria Ongari and Gualtiero Colombo and Flavia Turcatti and Anna Catania",
year = "2007",
month = "10",
doi = "10.1016/j.peptides.2007.08.001",
language = "English",
volume = "28",
pages = "2016--2022",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - The synthetic melanocortin (CKPV)2 exerts broad anti-inflammatory effects in human neutrophils

AU - Capsoni, Franco

AU - Ongari, Annamaria

AU - Colombo, Gualtiero

AU - Turcatti, Flavia

AU - Catania, Anna

PY - 2007/10

Y1 - 2007/10

N2 - Natural melanocortin peptides exert broad effects on the host and they have remarkable therapeutic potential. However, successful use of melanocortins as therapeutic agents depends on the design of molecules that have more stable pharmacological profiles. The synthetic peptide (CKPV)2, based on the C-terminal sequence of α-melanocyte stimulating hormone (α-MSH), has anti-tumor necrosis factor-α (TNF-α) effects in vitro and in vivo and is a promising candidate to treat inflammation. Because neutrophil activity is a major target for anti-inflammatory therapies, we determined whether (CKPV)2 modulates human neutrophil functions in vitro. Incubation of freshly-separated human neutrophils with 10-12-10-6 M (CKPV)2 significantly inhibited activities relevant to the inflammatory reaction. Neutrophil migration toward the two chemoattractants interleukin 8 (IL-8) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) was significantly inhibited by (CKPV)2. (CKPV)2 also inhibited reactive oxygen intermediate (ROI) production induced by phorbol 12-myristate 13-acetate (PMA), but not that induced by fMLP. Because these effects of (CKPV)2 were abolished by the adenylyl cyclase inhibitor 2′,5′-dideoxyadenosine (ddAdo), they appear to be cAMP-dependent. Finally, the peptide reduced lipopolysaccharide (LPS)-stimulated expression of TNF-α, interleukin-1β (IL-1β), interleukin-8 (IL-8), and intercellular adhesion molecule 1 (ICAM-1), as well as TNF-α protein release in cell supernatants. The data indicate that (CKPV)2 modulates broad cAMP-dependent, anti-inflammatory pathways in human neutrophils.

AB - Natural melanocortin peptides exert broad effects on the host and they have remarkable therapeutic potential. However, successful use of melanocortins as therapeutic agents depends on the design of molecules that have more stable pharmacological profiles. The synthetic peptide (CKPV)2, based on the C-terminal sequence of α-melanocyte stimulating hormone (α-MSH), has anti-tumor necrosis factor-α (TNF-α) effects in vitro and in vivo and is a promising candidate to treat inflammation. Because neutrophil activity is a major target for anti-inflammatory therapies, we determined whether (CKPV)2 modulates human neutrophil functions in vitro. Incubation of freshly-separated human neutrophils with 10-12-10-6 M (CKPV)2 significantly inhibited activities relevant to the inflammatory reaction. Neutrophil migration toward the two chemoattractants interleukin 8 (IL-8) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) was significantly inhibited by (CKPV)2. (CKPV)2 also inhibited reactive oxygen intermediate (ROI) production induced by phorbol 12-myristate 13-acetate (PMA), but not that induced by fMLP. Because these effects of (CKPV)2 were abolished by the adenylyl cyclase inhibitor 2′,5′-dideoxyadenosine (ddAdo), they appear to be cAMP-dependent. Finally, the peptide reduced lipopolysaccharide (LPS)-stimulated expression of TNF-α, interleukin-1β (IL-1β), interleukin-8 (IL-8), and intercellular adhesion molecule 1 (ICAM-1), as well as TNF-α protein release in cell supernatants. The data indicate that (CKPV)2 modulates broad cAMP-dependent, anti-inflammatory pathways in human neutrophils.

KW - α-Melanocyte stimulating hormone (α-MSH)

KW - (CKPV)

KW - Chemotaxis

KW - Human neutrophils

KW - Lipopolysaccharide (LPS)

KW - Melanocortin peptides

KW - Respiratory burst

UR - http://www.scopus.com/inward/record.url?scp=34548802959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548802959&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2007.08.001

DO - 10.1016/j.peptides.2007.08.001

M3 - Article

C2 - 17850921

AN - SCOPUS:34548802959

VL - 28

SP - 2016

EP - 2022

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 10

ER -